title: Role of selective cholesterol absorption inhibition in the management of dyslipidemia.
abstract: Ezetimibe, a cholesterol absorption inhibitor, lowered low-density lipoprotein cholesterol levels and improved high-density lipoprotein cholesterol and triglyceride levels when used as monotherapy or when coadministered with a statin in clinical trials, and its safety profile is similar to placebo or statin plus placebo. Addition of ezetimibe to ongoing statin therapy increased the proportion of patients reaching recommended low-density lipoprotein cholesterol treatment goals. Ezetimibe is an effective treatment option that may enable more patients with hypercholesterolemia to achieve optimal cholesterol levels and reduce their risk for coronary heart disease.
authors.affiliation: Department of Medicine, Baylor College of Medicine, 6565 Fannin Street, MS A-601, Suite A656B, Houston, TX 77030, USA. cmb@bcm.tmc.edu
authors.forename: Christie M
authors.initials: CM
authors.lastname: Ballantyne
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001384:Azetidines / Q000494:pharmacology*; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D000960:Hypolipidemic Agents; D000069438:Ezetimibe